Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 29,129 matching trials from the live ClinicalTrials.gov search.
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Breast Cancer
Interventions
Fludarabine, Cyclophosphamide, Cyclosporine, Natural killer cells, IL-2, Methylprednisolone, Interleukin-2
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
carmoterol (CHF 4226), salmeterol, placebo
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years to 75 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
24
States / cities
Jonesboro, Arkansas • Fresno, California • San Diego, California + 19 more
Conditions
Lupus Nephritis (LN)
Interventions
C-CAR168
Biological
Lead sponsor
AbelZeta Inc.
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rockville, Maryland
Conditions
Hereditary Angioedema
Interventions
CINRYZE
Biological
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
7
States / cities
Scottsdale, Arizona • Walnut Creek, California • Atlanta, Georgia + 4 more
Conditions
Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Interventions
CTIM-76
Drug
Lead sponsor
Context Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Little Rock, Arkansas • Beverly Hills, California • Denver, Colorado + 11 more
Conditions
Healthy Volunteers
Interventions
PF-04308515, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Apremilast for Alcohol Use Disorder Treatment in Women and Men

NCT06324435
Conditions
Alcohol Use Disorder
Interventions
Apremilast
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Myelodysplastic Syndromes, Myeloproliferative Chronic Myelomonocytic Leukemia
Interventions
Cladribine, Cytarabine, Venetoclax, Azacitidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hurler Syndrome, Fanconi Anemia, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Shwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia, Thalassemia Major, Hemophagocytic Lymphohistiocytosis, Sickle Cell Disease
Interventions
Abatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Neutropenia, Breast Cancer
Interventions
SPI-2012, Pegfilgrastim, Docetaxel, Cyclophosphamide
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
49
States / cities
Tucson, Arizona • Yuma, Arizona • Hot Springs, Arkansas + 46 more
Conditions
Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)
Interventions
Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF), Tacrolimus Capsules, Methylprednisone, Prednisone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
20
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 17 more
Conditions
Stroke, Acute
Interventions
Nerinetide (NA-1), 2.6 mg/kg, Placebo
Drug
Lead sponsor
NoNO Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Torrance, California + 17 more
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma
Interventions
Zanubrutinib, Rituximab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Rheumatoid Arthritis
Interventions
Infliximab, Methotrexate, Methylprednisolone, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more
Completed Phase 4 Interventional Results available

Omega-3 Supplementation to ADHD Medication in Children

NCT02204410
Conditions
Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation
Interventions
Omega-3 Fatty Acid, ADHD Medication
Dietary Supplement · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8, Stage II Urethral Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Urethral Urothelial Carcinoma
Interventions
Avelumab, Cisplatin, Fluorouracil, Mitomycin, Quality-of-Life Assessment, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Ischemic Heart Disease
Interventions
umbilical cord-derived mesenchymal stromal cells (UC-MSCs)
Biological
Lead sponsor
Roberto Bolli
Other
Eligibility
21 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Miami, Florida • Louisville, Kentucky • Houston, Texas
Conditions
Colorectal Cancer
Interventions
capecitabine
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
90
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
Conditions
Chronic Lymphocytic Leukemia
Interventions
Pembrolizumab, Ibrutinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Interventions
Blinatumomab, Low-intensity chemotherapy regimen, SOC chemotherapy regimen
Drug
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 100 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
7
States / cities
Duarte, California • Orange, California • San Francisco, California + 4 more
Conditions
Melanoma
Interventions
injection of mouse TYRP2 DNA
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
7 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Parkinson's Disease
Interventions
Levodopa, Zolpidem first dose, Zolpidem second dose, sugar pill
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
30 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
21
States / cities
Phoenix, Arizona • Sacramento, California • Ocala, Florida + 18 more
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of SLV213 for the Treatment of COVID-19.

NCT06146374
Conditions
COVID-19
Interventions
Placebo for SLV213, SLV213
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas